Situation: A nurse works in the pediatric ward and the adolescent health clinic of a city hospital during the rainy season. A sexually active 17-year-old girl is diagnosed with genital warts caused by human papillomavirus (HPV) types 6 and 11. Which points should the nurse include in her teaching plan? 1. These HPV types are low-risk types that rarely cause cancer 2. Treatment removes the warts but may not clear the virus 3. She no longer benefits from HPV vaccination because she is already infected 4. She will still need cervical cancer screening at the recommended age

HPV 6 and 11 are low-risk types that cause warts but rarely cancer, whereas high-risk types such as 16 and 18 cause most cervical cancers; she may carry more than one type, so screening under DOH guidance (women 30–65) still applies. Wart treatment removes lesions, not the virus. Infection with some types does not remove the benefit of vaccination, which still protects against types she has not acquired.

Clinical context
A 17-year-old sexually active adolescent presents with genital warts caused by HPV types 6 and 11. The teaching plan must address risk stratification, treatment expectations, vaccination, and future screening. The correct combination is 1, 2, and 4.

Why statement 1 is correct
HPV 6 and 11 are classified as low-risk HPV types. They are responsible for approximately 85% of all genital warts but are rarely associated with malignant transformation ^[2]. In contrast, high-risk types such as 16 and 18 account for about 70% of cervical cancers ^[2]. The presence of visible warts therefore does not by itself indicate a high oncogenic risk. However, rare cases of invasive carcinoma containing HPV 6 or 11 have been documented, so the term “low-risk” describes relative probability rather than absolute safety ^[3].

Why statement 2 is correct
Treatment for genital warts—whether topical, cryotherapy, or surgical excision—targets the visible lesion, not the underlying viral infection. Removing warts does not guarantee clearance of HPV from the surrounding epithelium. The virus can persist in a latent or subclinical state, which explains why recurrences occur even after successful lesion removal. This distinction is critical for patient education: the adolescent should understand that treatment improves symptoms and reduces transmission risk from visible lesions but does not equal cure.

Why statement 3 is incorrect
Infection with HPV 6 or 11 does not eliminate the benefit of vaccination. The quadrivalent vaccine covers 6/11/16/18, and the nonavalent vaccine covers 6/11/16/18/31/33/45/52/58 ^[2]. A patient already infected with one or two types can still receive protection against the other vaccine-covered types she has not yet acquired. Key point! Vaccination is not contraindicated by a history of genital warts; it remains a recommended preventive strategy for sexually active adolescents.

Why statement 4 is correct
Even though HPV 6 and 11 are low-risk, the adolescent may be co-infected with high-risk HPV types that are not visible as warts. A retrospective study of 407 women found that vulvar condyloma can serve as a marker for concurrent high-risk cervical HPV infection and abnormal cervical cytology ^[1]. The presence of genital warts should prompt continued adherence to age-appropriate cervical cancer screening, not early discontinuation. Screening recommendations remain applicable because the patient’s full HPV genotype profile is unknown without specific testing.

Integrated teaching plan

Teaching point	Clinical rationale	Nursing implication
Low-risk type explanation	HPV 6 and 11 cause warts but rarely cancer [2]	Reduce anxiety while avoiding false reassurance about all HPV
Treatment limitation	Lesion removal does not clear the virus	Set realistic expectations about recurrence
Vaccination still beneficial	Protects against types not yet acquired [2]	Offer vaccine regardless of current infection
Continued screening	Co-infection with high-risk types is possible [1]	Reinforce age-based cervical screening adherence

Watch out! Do not equate “low-risk HPV” with “no screening needed.” The coexistence of high-risk types is clinically significant and supports ongoing surveillance ^[1].